These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21075276)

  • 21. Common queries in thalassemia care.
    Panigrahi I; Marwaha RK
    Indian Pediatr; 2006 Jun; 43(6):513-8. PubMed ID: 16820660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of iron status.
    Pippard MJ
    Prog Clin Biol Res; 1989; 309():85-92. PubMed ID: 2675108
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 24. The treatment of beta-thalassemia: organization.
    Masera G
    Birth Defects Orig Artic Ser; 1982; 18(7):325-8. PubMed ID: 7159741
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatic iron stores in thalassemia: non-invasive magnetic measurements.
    Brittenham GM; Allen CJ; Farrell DE; Harris JW
    Prog Clin Biol Res; 1989; 309():101-6. PubMed ID: 2780744
    [No Abstract]   [Full Text] [Related]  

  • 26. Thalassemia syndromes. Recent advances.
    Ohene-Frempong K; Rappaport E; Schwartz E
    Hematol Oncol Clin North Am; 1987 Sep; 1(3):503-19. PubMed ID: 3329184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 28. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac complications in homozygous beta-thalassemia.
    Wonke B; Hoffbrand AV; Aldouri MA; Ward SE
    Prog Clin Biol Res; 1989; 309():51-6. PubMed ID: 2780750
    [No Abstract]   [Full Text] [Related]  

  • 30. MRI and iron-overload cardiomyopathy in thalassaemia.
    Pennell D
    Circulation; 2006 Mar; 113(11):f43-4. PubMed ID: 16552847
    [No Abstract]   [Full Text] [Related]  

  • 31. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
    Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Respiratory function tests in adolescents with beta-thalassemia major (author's transl)].
    Secchi GC; Scotti PG; Cambiaghi G; Aresini G; De Carli A; Guerrieri MC
    Haematologica; 1982 Feb; 67(1):23-32. PubMed ID: 6800901
    [No Abstract]   [Full Text] [Related]  

  • 33. Managing thalassemia in the developing world: an evidence-based approach for prevention, transfusion independency, and curative treatment with hematopoietic stem cell transplantation.
    Ansari SH; Parveen S; Siddiqui S; Perveen K; Ahmed G; Kaleem B; Ahmed S; Zohaib M; Farzana T; Shamsi T
    Blood Adv; 2018 Nov; 2(Suppl 1):42-45. PubMed ID: 30504199
    [No Abstract]   [Full Text] [Related]  

  • 34. Current management of homozygous beta thalassemia.
    Choudhry VP; Desai N; Pati HP; Nanu A
    Indian Pediatr; 1991 Oct; 28(10):1221-9. PubMed ID: 1724659
    [No Abstract]   [Full Text] [Related]  

  • 35. Survival of a hydropic infant with homozygous alpha-thalassemia-1.
    Beaudry MA; Ferguson DJ; Pearse K; Yanofsky RA; Rubin EM; Kan YW
    J Pediatr; 1986 May; 108(5 Pt 1):713-6. PubMed ID: 3701517
    [No Abstract]   [Full Text] [Related]  

  • 36. Liver iron stores before and after bone marrow transplantation for thalassemia.
    Politi P; Lucarelli G; Capriotti L; Salvadori P; Dardanelli C; Barbanti I
    Prog Clin Biol Res; 1989; 309():281-9. PubMed ID: 2675096
    [No Abstract]   [Full Text] [Related]  

  • 37. Decreased natural killer activity in thalassemia major: a possible consequence of iron overload.
    Akbar AN; Fitzgerald-Bocarsly PA; de Sousa M; Giardina PJ; Hilgartner MW; Grady RW
    J Immunol; 1986 Mar; 136(5):1635-40. PubMed ID: 3005397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Beta-thalassemia: molecular bases, physiopathology, prevention and treatment].
    Cao A
    Minerva Pediatr; 1991 Dec; 43(12):745-51. PubMed ID: 1798400
    [No Abstract]   [Full Text] [Related]  

  • 39. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thalassemia incidence and treatment in China with special reference to Shenzhen City and Guangdong province.
    Li CG; Li CF; Li Q; Li M
    Hemoglobin; 2009; 33(5):296-303. PubMed ID: 19814675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.